Vertex Pharmaceuticals

Registered Principal Details

Business Or Interest:
Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative new medicines so people with serious diseases can lead better lives.

Lobbying Interests:
Engage on access issues relating to non-opioid Pain Alternatives; access to healthcare; Awareness activities specific to Cystic Fibrosis, Sickle Cell Disease, T1D, Kidney Disease, and Pain.

CEO Name:
Reshma Kewalramani

Contact
EB
Elizabeth Brunsvold
50 Northern Avenue
Boston, MA 20001
(312) 835-9997
Libby_Brunsvold@vrtx.com
http://www.vrtx.com

Authorized Lobbyists

Lobbyist Name Exclusive Duties Authorized On Withdrawn On

Lobbying Interests

Legislative Bills/Resolutions

Assembly Bill 173
Assembly Bill 173
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)

Bill Text and History

For
Notification Date
4/14/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Senate Bill 203
Senate Bill 203
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)

Bill Text and History

For
Notification Date
4/21/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.

Budget Bill Subjects

Health Services: Medicaid Services
Biennial budget bill treatment of matter relating to
Health Services: Medicaid Services

Notification Date
2/27/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.

Insurance: Departmentwide
Biennial budget bill treatment of matter relating to
Insurance: Departmentwide

Notification Date
2/27/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.

Insurance: Supervision of the Insurance Industry
Biennial budget bill treatment of matter relating to
Insurance: Supervision of the Insurance Industry

Notification Date
2/27/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.

Topics Not Yet Assigned A Bill Or Rule Number

Development, drafting or introduction of a proposal relating to the treatment of nonopioid drugs and the development of a pain management access plan
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal relating to the treatment of nonopioid drugs and the development of a pain management access plan

Action Intended To Affect
Legislative matter

Notification Date
3/12/2025
First Communication Date
3/6/2025
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has communicated on this matter.

Development, drafting or introduction of a proposal related to sickle disease awareness month.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal related to sickle disease awareness month.

Action Intended To Affect
Both Legislative matter and rule

Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.

Development, drafting or introduction of a proposal related to the treatment of sickle cell disease
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal related to the treatment of sickle cell disease

Action Intended To Affect
Both Legislative matter and rule

Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.

Development, drafting or introduction of a proposal Medicaid drug coverage process and procedure.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal Medicaid drug coverage process and procedure.

Action Intended To Affect
Both Legislative matter and rule

Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.

Development, drafting or introduction of a proposal related to the creation of a rare disease advisory council.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal related to the creation of a rare disease advisory council.

Action Intended To Affect
Both Legislative matter and rule

Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.

Development, drafting or introduction of a proposal relating to regulation of pharmaceutical manufacturers.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal relating to regulation of pharmaceutical manufacturers.

Action Intended To Affect
Both Legislative matter and rule

Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.

Development, drafting or introduction of a proposal relating to treatment of cyclic fibrosis.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal relating to treatment of cyclic fibrosis.

Action Intended To Affect
Both Legislative matter and rule

Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.

Total Lobbying Effort

No certified reports found.

Percent Allocation of Lobbying Effort

Legislative Bills/Resolutions

No legislative bills/resolutions found.

Budget Bill Subjects

No budget bill subjects found.

Administrative Rulemaking Proceedings

No administrative rulemaking proceedings found.

Topics Not Yet Assigned A Bill Or Rule Number

No topics found.

Minor Efforts

No minor efforts found.

Other Matters

No other matters found.

Filed Statements of Lobbying Activity and Expenditures